In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Progenics, Wyeth develop GI compound MNTX; ends

Executive Summary

Progenics licensed Wyeth Pharmaceuticals exclusive worldwide development and commercialization rights to its methylnaltrexone (MNTX) to treat side effects induced by opioid pain treatments. The deal enables Wyeth to further expand its reach into the gastroenterology field.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Royalty or Profit Split Information
    • Co-Promotion

Related Companies

Advertisement
UsernamePublicRestriction

Register